Trial Profile

Phase 1/2 study of JAB-8263 for the treatment of autoimmune diseases

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JAB-8263 (Primary)
Indications Autoimmune disorders
Focus Adverse reactions

Most Recent Events

22 Jul 2025 New trial record
03 Jul 2025 According to a Jacobio Pharmaceuticals media release, the company had submitted a Phase I/II IND application for JAB-8263 for the treatment of autoimmune diseases to the Center for Drug Evaluation (CDE) in China and it has been accepted. According to new regulatory guidelines, the review of of this IND application is expected to be completed within 30 working days

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com